Market Access/ News/ News Seagen’s breast cancer drug Tukysa turned down by NICE Phil Taylor breast cancer, HEOR, her2, NICE, Oncology, Seagen, Tukysa 0 Comment NICE has decided not to recommend Seagen’s orally-active HER2 inhibitor Tukysa for advanced breast cancer in draft guidance, Share X Seagen’s breast cancer drug Tukysa turned down by NICE https://pharmaphorum.com/news/seagens-breast-cancer-drug-tukysa-turned-down-by-nice/
News/ News/ Oncology Seattle Genetics snags early approval for advanced breast cancer drug Richard Staines breast cancer, fda, Seattle Genetics, Tukysa 0 Comment The FDA has approved Seattle Genetics’ breast cancer drug Tukysa (tucatinib) four months early, including in certain patients Share X Seattle Genetics snags early approval for advanced breast cancer drug https://pharmaphorum.com/news/fda-approves-seattle-genetics-advanced-breast-cancer-drug/
breast cancer, HEOR, her2, NICE, Oncology, Seagen, Tukysa
0 Comment
